ICU Medical (NASDAQ:ICUI) Upgraded by Wall Street Zen to Buy Rating

ICU Medical (NASDAQ:ICUI) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Monday.

A number of other research firms have also recently issued reports on ICUI. KeyCorp upped their price objective on shares of ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Piper Sandler upped their target price on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $175.67.

ICU Medical Stock Performance

ICUI opened at $156.17 on Monday. The firm has a market cap of $3.86 billion, a P/E ratio of -503.76 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.19 and a current ratio of 2.45. ICU Medical has a 52-week low of $107.00 and a 52-week high of $175.51. The business’s fifty day moving average is $145.37 and its 200-day moving average is $132.12.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, beating the consensus estimate of $1.43 by $0.60. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The company had revenue of $533.30 million during the quarter, compared to analysts’ expectations of $511.46 million. During the same period in the previous year, the company earned $1.59 EPS. The business’s revenue for the quarter was down 8.9% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. Sell-side analysts expect that ICU Medical will post 4.11 EPS for the current fiscal year.

Insider Buying and Selling

In other ICU Medical news, VP Virginia Ruth Sanzone sold 930 shares of the company’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total value of $132,376.20. Following the completion of the sale, the vice president directly owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. This represents a 14.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Elisha W. Finney sold 1,285 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the transaction, the director owned 3,995 shares in the company, valued at $560,977.90. The trade was a 24.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.50% of the stock is owned by company insiders.

Institutional Trading of ICU Medical

Large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC raised its stake in shares of ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after buying an additional 690,694 shares during the period. River Road Asset Management LLC grew its stake in ICU Medical by 207.0% during the second quarter. River Road Asset Management LLC now owns 651,492 shares of the medical instruments supplier’s stock valued at $83,658,000 after acquiring an additional 439,263 shares in the last quarter. Norges Bank bought a new position in shares of ICU Medical in the second quarter worth $36,633,000. UBS Group AG raised its holdings in shares of ICU Medical by 239.8% in the 3rd quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock valued at $46,371,000 after acquiring an additional 272,782 shares in the last quarter. Finally, William Blair Investment Management LLC bought a new stake in ICU Medical during the second quarter valued at approximately $27,928,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.